What Carnegie Pharmaceuticals does

Carnegie Pharmaceuticals is a privately held manufacturer of pharmaceutical drugs, founded in 2015 and operating with a headcount in the 11-50 employee range. Its corporate website (carnegiepharma.com) is the primary public touchpoint; however, the available source records indicate that this site returned only an anti-bot verification challenge, yielding no substantive product, regulatory, operational, or commercial content. The firm has no disclosed app, no published API, and no documented SDK or integration surface.

The recorded headquarters metadata is internally inconsistent — the source lists "New Jersey" as the city and "Trinidad and Tobago" as the country, an arrangement that appears to be a data-quality anomaly rather than a verified geographic footprint. No parent company, subsidiaries, management team roster, customer logos, pricing model, distribution channels, or compliance certifications are present in any input block. There are likewise no recorded funding rounds, mergers or acquisitions, partnerships, regulatory actions, product launches, or leadership changes.

Taken together, the only characterizable facts are firmographic: small, privately held, profit-seeking pharmaceutical drug manufacturer, founded roughly a decade ago, with a minimal public footprint. The absence of substantive first-party disclosure means that the operating profile — including business model mechanics, product mix, technology stack, and customer base — cannot be substantiated from the supplied material beyond the surface classification as a drug manufacturer.

Name

Carnegie Pharmaceuticals

Website

https://carnegiepharma.com

Company type

Private

Founded year

2015

Headcount range

51–100 employees

Short description

Carnegie Pharmaceuticals is a privately held pharmaceutical drug manufacturer founded in 2015, employing 11 to 50 people. Available source data does not disclose its specific product portfolio, customer base, business model, or ownership structure.

Ownership category

akta.pro rank

Headquarters

HQ city

New Jersey

HQ country

Trinidad & Tobago

HQ region

Latin America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D

Core offering

Carnegie Pharmaceuticals is a manufacturer of pharmaceutical drugs. The company produces drug products intended for the pharmaceutical market.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical drugs

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Sandoz: Novartis's generics and biosimilars division, one of the largest global producers of off-patent finished dosage forms. Comparable to Carnegie as a finished-dose generics manufacturer, but operating at an order-of-magnitude greater scale across highly regulated markets.
• Mallinckrodt: Specialty pharmaceutical manufacturer with branded and generic finished-dose products, including controlled substances and hospital-facing therapies. Comparable to Carnegie as a finished-dose pharmaceutical manufacturer, though at materially larger scale and with deeper regulatory infrastructure.
• Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a broad finished-dose portfolio and global distribution. Comparable to Carnegie only as an industry benchmark for generic finished-dose manufacturing; not a direct competitor given scale differential.
• Sun Pharmaceutical Industries: One of the largest generic pharmaceutical manufacturers globally, with a broad finished-dose portfolio and significant U.S. presence. Comparable as a generics finished-dose manufacturer, though operating at a scale and breadth that dwarfs a small private manufacturer like Carnegie.

Direct peers

• Hikma Pharmaceuticals: Multinational generic and specialty pharmaceutical manufacturer with strong presence in the Middle East, North Africa, and the U.S. Comparable to Carnegie given its broad finished-dose generics portfolio across both regulated and emerging markets — a relevant model for a Caribbean-domiciled manufacturer.
• Glenmark Pharmaceuticals: India-headquartered generic and specialty pharmaceutical manufacturer with global distribution, producing finished formulations in multiple therapeutic areas. Comparable to Carnegie as a finished-dose generic manufacturer with international reach, though at much larger scale.
• Amneal Pharmaceuticals: U.S. generic and specialty pharmaceutical manufacturer producing a broad range of finished dosage forms (oral solids, injectables, topicals). Comparable to Carnegie as a finished-dose manufacturer selling into similar distribution channels, though operating at materially larger scale.
• Aurobindo Pharma: India-based vertically integrated generic pharmaceutical manufacturer with a broad finished-dose portfolio exported globally. Comparable to Carnegie because both manufacture generic finished dosage forms; Aurobindo represents the export-oriented model Carnegie might emulate.
• Lannett Company: U.S.-based small-cap generic pharmaceutical manufacturer with a similarly modest product portfolio and headcount profile, selling finished dosage forms through wholesalers and distributors. Comparable to Carnegie because both are private/small-cap finished-drug manufacturers dependent on regulatory approvals and channel partnerships for revenue.
• Apotex: Large privately-held Canadian generic pharmaceutical manufacturer producing finished dosage forms across multiple therapeutic categories. Comparable to Carnegie as a private, generics-focused finished-drug manufacturer, though at substantially greater scale and geographic reach.

Market position

Strengths2 records

Weaknesses5 records

Key risks6 records

Key highlights2 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Carnegie Pharmaceuticals